archive-ie.com » IE » N » NCPE.IE

Total: 381

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • NCPE Dexamethasone Intravitreal Implant (Ozurdex®) Assessment | National Centre for Pharmacoeconomics
    in the treatment of macular oedema following Retinal Vein Occlusion Rapid Review Commenced Completed Outcome 12 11 2010 16 12 2010 Full Pharmacoeconomic Evaluation Recommended Pharmacoeconomic Evaluation Commenced Completed Outcome 24 11 2011 16 03 2012 Reimbursement Not Recommended We believe that at the submitted price Ozurdex cannot be considered cost effective therapy for the treatment of macular oedema following retinal vein occlusion Ozurdex Summary July 2013 Following resubmission of

    Original URL path: http://www.ncpe.ie/drugs/dexamethasone-intravitreal-implant-ozurdex/ (2015-10-30)
    Open archived version from archive

  • NCPE Carbazitaxel (Jevtana®) Assessment | National Centre for Pharmacoeconomics
    Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Economic Evaluation of cabazitaxel Jevtana for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with docetaxel containing treatment regimen Rapid Review Commenced Completed Outcome 02 06 2011 09 06 2011 Full Pharmacoeconomic Evaluation Recommended Pharmacoeconomic Evaluation Commenced Completed Outcome 03 11 2011 13 03 2012 Reimbursement not recommended at the submitted price The NCPE believe

    Original URL path: http://www.ncpe.ie/drugs/carbazitaxel-jevtana-for-prostate-cancer/ (2015-10-30)
    Open archived version from archive

  • NCPE Rivaroxaban (Xarelto®) Assessment | National Centre for Pharmacoeconomics
    of Deep Vein Thrombosis In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Economic evaluation of Rivaroxaban Xarelto for the Treatment of Deep Vein Thrombosis DVT and prevention of recurrent DVT and pulmonary embolism PE following an acute DVT in adults Rapid Review Commenced Completed Outcome 17 08 2011 31 08 2011 Full Pharmacoeconomic Evaluation Recommended Pharmacoeconomic Evaluation Commenced Completed Outcome 28 11 2011 24

    Original URL path: http://www.ncpe.ie/drugs/rivaroxaban-xarelto-for-dvt/ (2015-10-30)
    Open archived version from archive

  • CPE News Pneumococcal Conjugate Vaccination Strategy in Ireland. | National Centre for Pharmacoeconomics
    Templates Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Pneumococcal Vaccination In this Section About Us Current Staff News Glossary Contact Us Vacancies Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland PCV13 is the most cost effective option if the analysis is based on a serotype distribution reflecting 2011 data download document

    Original URL path: http://www.ncpe.ie/news/pneumococcal-vaccination/ (2015-10-30)
    Open archived version from archive

  • NCPE Telapravir Assessment | National Centre for Pharmacoeconomics
    Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Economic evaluation of Telaprevir Incivo as add on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1 Rapid Review Commenced Completed Outcome 28 10 11 02 11 11 Full Pharmacoeconomic Evaluation Recommended Pharmacoeconomic Evaluation Commenced Completed Outcome 08 11 2011 19 01 2012 Reimbursement Recommended We consider telaprevir Incivo a highly

    Original URL path: http://www.ncpe.ie/drugs/telapravir/ (2015-10-30)
    Open archived version from archive

  • NCPE Boceprevir (Victrelis®) Assessment | National Centre for Pharmacoeconomics
    Research ICORN Education Boceprevir Victrelis In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Economic evaluation of Boceprevir Victrelis as add on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1 Pharmacoeconomic Evaluation Commenced Completed Outcome 19 08 2011 17 01 2012 Reimbursement Recommended We consider boceprevir a highly cost effective therapy when added to peginterferon ribavirin

    Original URL path: http://www.ncpe.ie/drugs/boceprevir-victrelis/ (2015-10-30)
    Open archived version from archive

  • NCPE Denosumab (Xgeva®) Assessment | National Centre for Pharmacoeconomics
    Utilisation Research Pharmacoeconomic Research ICORN Education Denosumab Xgeva In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Cost effectiveness of denosumab Xgeva for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland Pharmacoeconomic Evaluation Commenced Completed Outcome 15 08 2011 08 12 2011 Reimbursement Recommended We consider denosumab Xgeva a cost effective therapy for the prevention of skeletal

    Original URL path: http://www.ncpe.ie/drugs/denosumab-xgeva-3/ (2015-10-30)
    Open archived version from archive

  • NCPE Ticagrelor (Brilique®) | National Centre for Pharmacoeconomics
    Diagnostics and Other Technologies Archive Economic Evaluation of Ticagrelor Brilique for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome ACS including patients managed medically and those who are managed with PCI Percutaneous Coronary Intervention or CABG Coronary Artery Bypass Graft Rapid Review Commenced Completed Outcome 25 11 2010 20 01 2011 Full Pharmacoeconomic Evaluation Recommended Pharmacoeconomic Evaluation Commenced Completed Outcome 27 07 2011 10 10 2011

    Original URL path: http://www.ncpe.ie/drugs/ticagrelor-brilique/ (2015-10-30)
    Open archived version from archive